GDF11 was called young blood's rejuvenation factor. A rival lab could not reproduce it.

GDF11 is a blood protein that a series of celebrated mouse studies cast as a genuine "rejuvenation factor," reported to reverse ageing of the heart, skeletal muscle and brain when restored to youthful levels in old animals [s1][s2][s3]. Within a year a second laboratory could not reproduce the muscle result, found that the tools used to measure GDF11 were not specific to it, and argued the protein actually rises with age and blocks muscle repair — and to this day no human trial has tested it as an anti-ageing treatment [s4]. It is a case study in how a striking finding becomes a headline before the science has settled.

Where the excitement came from

The story began with parabiosis, the surgical joining of a young and an old mouse so they share a bloodstream. In 2013 a Harvard-led group reported that after four weeks of exposure to a young circulation, age-related thickening of the heart in old mice dramatically regressed, and that the effect was carried by a blood-borne factor they identified, using aptamer-based proteomics, as GDF11 — a member of the TGF-β family that they found declined with age [s1]. Restoring GDF11 in old mice to youthful levels reproduced the benefit, which they framed as a therapeutic opportunity for the ageing heart [s1].

The following year the same circle extended the claim. One Science paper reported that supplementing GDF11 — by parabiosis or by injecting recombinant protein — restored the function and genomic integrity of aged muscle stem cells and improved the structure, strength and endurance capacity of old muscle [s2]. A companion paper reported that young systemic factors, GDF11 among them, rejuvenated the blood vessels and generated new neurons in the ageing mouse brain [s3]. Three organs, one protein, all pointing the same way: it was an irresistible narrative, and it drove a wave of coverage and commercial interest in "young blood."

The rebuttal

Then the reproducibility problem surfaced. In 2015 a group at Novartis set out to replicate the muscle work and could not [s4]. They reported that the antibody reagents used in the earlier studies to detect GDF11 were not specific to it — they also picked up myostatin, a closely related protein that suppresses muscle growth — so the earlier measurements may not have been tracking GDF11 at all [s4]. Building a GDF11-specific immunoassay, they found a trend toward increased GDF11 in the blood of aged rats and humans, the opposite of the decline the original work described, and rising GDF11 messenger RNA in ageing rat muscle [s4].

Their functional results inverted the picture too. GDF11 and myostatin, they showed, act through the same downstream machinery — both switch on SMAD2/3 signalling and inhibit the differentiation of muscle precursor cells — and in their hands GDF11 significantly inhibited muscle regeneration and reduced the expansion of muscle stem cells in mice [s4]. Far from a youth-restoring tonic, GDF11 looked to them like a candidate to block pharmacologically in age-related muscle loss [s4].

Why the two accounts diverge

The dispute has never been cleanly resolved, and the likeliest explanation is mundane: measuring GDF11 is hard. Because it is so similar to myostatin, an assay that cannot separate the two will report a mixture, and small differences in reagents, doses and animal models can flip the apparent direction of a subtle effect [s1][s4]. That is exactly the kind of fragility that should lower confidence in any single dramatic result — and it is why independent replication, not the splash of the first paper, is the thing to wait for.

The episode also fits a recurring pattern in longevity science, where a molecule that shifts with age is quickly promoted from correlate to cause to cure. The same reproducibility trap has since undone other ageing "biomarkers," including the claim that blood taurine falls with age and drives it. A marker moving with age is a starting point for investigation, not evidence that topping it up will make anyone younger.

What it means for a reader

The honest status of GDF11 is unsettled biology with no human evidence behind the hype. Every positive result is in mice; every claim that it rejuvenates the heart, muscle or brain comes from animal work that a second laboratory disputes; and the direction the protein even moves with age is contested [s1][s2][s3][s4]. No randomised human trial has shown that raising or lowering GDF11 does anything for health or lifespan, so any product or clinic invoking it as a proven "young blood" factor is selling ahead of the data.

GDF11's appeal traces to the broader parabiosis story, whose human translation — plasma exchange and "young plasma" infusions — remains thin and largely unproven in people. It sits within the wider framework of the hallmarks of ageing, specifically the altered signalling between cells and the exhaustion of stem cells, which are real phenomena. What to watch is whether a specific, replicated mechanism and a validated assay ever turn GDF11 from a contested mouse result into something testable in humans. Until then, the accurate summary is that it reversed ageing in a press release, not in a person.